Rebirth: Super Banking System Chapter 2382 - 2222: Soaring
Previously on Rebirth: Super Banking System...
Right now.
Big pharmaceutical firms from Europe and the US are experiencing a bitter taste, like they've swallowed filth.
Deep sorrow.
Utter rage.
They itch to lash out at someone! Over these past months, they've desperately wished for a health mishap to strike, allowing them to slam and block the rollout harshly.
Yet.
Reality shows they've worried too much. Up to now, no treated individuals have displayed negative side effects, and notably, numerous critical cases are now walking around.
On daily broadcasts.
This day.
Three recoveries.
Next day.
Five more.
The following day.
Dozens... Repeatedly, it hammers at their sanity—folks bedridden for years, unable to fend for themselves, now boast sharp wits.
Chatting away.
Exchanging words.
Engaging in spirited talks.
Blast it!
Couldn't your remedy's power be toned down a notch?
"Xie Te."
"Fuck."
"Damn."
"..."
Within their workplaces, they've spat out these profanities countless times, the fury boiling inside! It severs a massive revenue stream all for that slim gain.
This remedy.
Under their control, profits would multiply over tenfold beyond what Myanmar Medical Group pulls in today, perhaps far higher. They yearn to confront that firm.
Propose:
Triple the sum.
No.
Quintuple the price now, hand it over to us, we'll prosper side by side—the near-billion-dollar deal from Huaxia flashing in reports feels within reach.
But.
From their perspective.
Like common greens!
Practically giveaway!
Lazy pricing!
In their hands, it'd fetch no less than fifty billion USD, close to four hundred billion RMB, yet it's peddled for just six hundred million, even if not theirs, the ache stings!
The deeper they dwell, the sharper the sting, squandering vital assets!
...
At the same time.
In America.
Washington.
White House.
Amid public pressures, the President—serving beyond a year and centering his tenure on health reforms—chuckles to himself.
Hard to fathom earlier.
Simply because.
Big money interests.
Those drug behemoths wield immense sway, challenging them spells trouble, but circumstances have shifted, with Myanmar Medical Group shattering the status quo.
To start.
Transcription Fluid.
It slashes funding needs for cancers and blood disorders dramatically, a true boon, though he fretted the tycoons might intervene.
Still.
Truth reveals: The tycoons are relishing the spectacle!
Fine.
Though baffling, it aligns with his goals. Now, the Alzheimer's cure's arrival brings yet another surprise windfall.
Hence.
Massive savings ahead.
"I believe we ought to heed the people's voice and greenlight the approval—what's your take?"
"Fine."
"Agreed."
"..."
His advisors back it fully; the swell of sentiment is unstoppable. Crucially, the drug titans appear to have dropped their fight.
No pressure tactics.
No barriers.
No sneaky moves.
Thus.
They're all in sync, yet a few fret over potential issues.
For that.
One swiftly suggests a fix, "Easy, have families sign release forms prior to therapy, they bear the hazards, we stay clear."
"Plus."
"Limit suggestions to critical cases only. For initial or moderate stages, we won't push the new therapy option."
At those words.
All heads nod in agreement.
This issue.
They aim to dodge any fallout; the drug powerhouses act calm presently, but who can tell their schemes—better stay vigilant.
Right now, chief objectors remain kin of dire sufferers.
In essence.
Playing safe works best.
...
Three days on.
News leaks from Washington: Officials collectively approve targeted Alzheimer's therapies just for grave cases at home.
Right away.
Debates erupt among the masses.
"Grave cases? And the lighter ones?" a voice challenges.
Quickly.
A reply comes.
"Head straight to Myanmar, clearly the White House shuns heavy liability, rolling out this targeted version is risky by nature."
"Sly move."
"Classic White House."
"Yep."
"..."
Beyond gripes, folks aren't overly fussed, it's progress nonetheless, and for milder or moderate afflicted, a Myanmar jaunt sounds appealing.
Truth be told.
Myanmar.
Has risen as a top global spot for trips, sufferers tend to be older. For seniors, touring the globe while mending health is ideal!
So.
Satisfaction prevails.
"Touring Myanmar's fine too, to witness that wondrous land, and Huaxia—never set foot in Asia before, time to explore."
"True enough."
"Hurry, snag those flights quick, or it'll drag to next term."
"..."
Suddenly.
Plenty of observers, noting the targeted drugs skip early or mid levels, rush to reserve via Myanmar Medical Group's site.
Next.
Per the schedule, they secure air travel and stays.
...
Across Europe.
Certain nations.
Two days hence, they too issue matching exceptions, restricting home use to dire instances only. Locals eye this and adapt swiftly, no big deal.
A journey.
Proves enjoyable enough.
Concurrently.
Further lands join in, as Europe and the US proceed, they can't lag, it looks off otherwise. Many opt for full rollout.
Initial phase.
Intermediate phase.
Advanced phase.
All handleable locally. Such nations chiefly span Africa, first to oblige big backers with goodwill, second lacking alternatives.
Already strapped for cash, traveling to Myanmar.
- Airfare.
- Meals and rooms.
- Remedies.
- Extras.
These four drain their forex heavily, better to import outright, cutting three key costs—thrift means gain.
No way around it.
Destitute.
Must scrimp to survive!
...
In this manner.
Within two weeks.
More than eighty nations and areas worldwide greenlight importing Alzheimer's therapies for local severe case handling, and soon after.
Come the requests.
Three hundred units.
Five hundred.
A thousand.
Fifteen hundred.
...
By March's midpoint, Myanmar Medical Group tallies orders past 1.8 trillion RMB, hurtling toward thirty billion USD.
This sum sparks jealousy elsewhere.
But.
For European and American drug moguls, it's not just a trickle of loss, but a gushing wound. Due to it, Myanmar Medical Group's shares rocket upward.
Over two weeks.
A thirty percent jump.
Atop its solid valuation, that's quite the feat.
Consequently.
Huaxia's horde of stock traders buzz with thrill.
"Haha, struck gold once more."
"Awesome!"
"This outfit never lets down, I fretted Transcription Fluid might cap it, but who knew they'd pull this ace."
"Incredible!"
"Jealous!"
"Alas! Cashed out prematurely!"
"..."
Thrills.
Joy.
Regrets.
A mix of feelings surges, via Myanmar's markets, loads struck it rich, sure, some deemed it peaked and bailed.
Today.
They can't avoid second thoughts.
"Myanmar shares remain rock-solid truly, from launch day, they've climbed without fail, and chiefly through real worth, not hype tricks."
"That time!"
"Jumped in at debut, a million invested now yields at least six million back, oh well! Had I foreseen, I'd have held tight for steady wins."